Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ALTAIR: trifluridine/tipiracil versus placebo when ctDNA becomes positive after resection of colorectal cancer

Phase 3 randomized trial of trifluridine/tipiracil versus placebo in patients with resected colorectal cancer who test ctDNA-positive without radiographic recurrence. ClinicalTrials.gov lists the study as completed.

National Cancer Center Hospital East